What is MRD?
Even if you are responding well to treatment or are in remission, a small number of cancer cells can remain in your body, and may cause your disease to return. This is called measurable (or minimal) residual disease, also known as MRD.LEARN MORE ABOUT MRD
clonoSEQ for Patients
With MRD testing, you and your doctor have a personalized way to track—and talk about—your body’s individual response to treatment.LEARN MORE ABOUT MRD
clonoSEQ for Clinicians
clonoSEQ leverages the power of next-generation sequencing (NGS) and offers an accurate and reliable way to assess how disease burden changes over time in response to treatment or during remission.How clonoSEQ works
News and Updates
Adaptive Biotechnologies Announces New Clinical Data Demonstrating Impact of clonoSEQ® Assay on Patients with Blood Cancers at the 62nd ASH Annual Meeting
MRD assessment with clonoSEQ improves outcomes both for patients and the healthcare system, as patients with undetectable MRD may be able to discontinue active treatment.
Adaptive Biotechnologies Receives Expanded FDA Clearance for the clonoSEQ® Assay to Assess Minimal Residual Disease (MRD) in Patients with Chronic Lymphocytic Leukemia.View Press Release
Adaptive Biotechnologies and Microsoft launch virtual ImmuneRACE study to inform novel COVID-19 diagnostics to address unmet needs in testing.View Press Release
What We’re SharingFollow Us
Adaptive now offers mobile phlebotomy via @Phlebotek to collect clonoSEQ MRD blood draws from patients at home. clonoSEQ is FDA-cleared to assess MRD in patients with CLL, MM, or B-ALL. For important info. incl. sample types & test limitations: https://t.co/sE39cuZxFD pic.twitter.com/4GCA1BJGPZ
— clonoSEQ (@clonoSEQ) December 6, 2020
This page is intended for use by healthcare professionals of the United States.
clonoSEQ® is available as an FDA-cleared in vitro diagnostic (IVD) test service provided by Adaptive Biotechnologies to detect measurable residual disease (MRD) in bone marrow from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL) and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). clonoSEQ is also available for use in other lymphoid cancers as a CLIA-validated laboratory developed test (LDT) service. For important information about the FDA-cleared uses of clonoSEQ including test limitations, please visit clonoSEQ.com/technical-summary.
Make an inquiry to learn more about our products.